Skip to main content
Figure 4 | Diabetology & Metabolic Syndrome

Figure 4

From: CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models

Figure 4

CNX-013-B2 reduces body weight and enhances non-shivering thermogenesis. A- Body weight in DIO mice, B-Absolute adipose depot weight, C- mesenteric adipocyte size, D- Body weight gain in ob/ob mice, E-.Cold temperature tolerance in DIO mice, F- SDH activity in gastrocnemius muscle of DIO mice, G and H-, UCPI expression levels in inguinal and brown adipocyte, I- H&E of adipocytes and J-UCP1 quantification in inguinal adipocytes. All the values are expressed as Mean ± SEM; one way analysis of variance followed by Dunnett’s test for representing significance value of the treatment groups. P value significance was represented as (*) <0.05, (**) <0.01 and (***) <0.001 when compared with DIO control. (#) <0.05, (##), <0.01 and (###) <0.001 as compared to lean or ob/+.

Back to article page